cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Celcuity Inc
3 own
2 watching
Current Price
$17.11
$0.26
(1.54%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
322.25M
52-Week High
52-Week High
22.18800
52-Week Low
52-Week Low
8.38900
Average Volume
Average Volume
0.29M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization322.25M
icon52-Week High22.18800
icon52-Week Low8.38900
iconAverage Volume0.29M
iconDividend Yield--
iconP/E Ratio--
What does the Celcuity Inc do?
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company s CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Read More
How much money does Celcuity Inc make?
News & Events about Celcuity Inc.
Accesswire
1 year ago
MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual...
Accesswire
1 year ago
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational statusMINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc. (Nasdaq:CELC...
Accesswire
1 year ago
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference.Brian Sullivan, Chairman, Chief...
TipRanks Financial Blog
1 year ago
Celcuity (CELC Research Report) received a Buy rating and price target from Craig-Hallum analyst Alexander Nowak on March 21. The companys share... Celcuity (CELC Research Report) received a Buy rating and price target from Craig-Hallum analyst...
Frequently Asked Questions
Frequently Asked Questions
What is Celcuity Inc share price today?
plus_minus_icon
Can Indians buy Celcuity Inc shares?
plus_minus_icon
How can I buy Celcuity Inc shares from India?
plus_minus_icon
Can Fractional shares of Celcuity Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Celcuity Inc stocks?
plus_minus_icon
What is today’s traded volume of Celcuity Inc?
plus_minus_icon
What is today’s market capitalisation of Celcuity Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Celcuity Inc?
plus_minus_icon
What percentage is Celcuity Inc down from its 52-Week High?
plus_minus_icon
What percentage is Celcuity Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$17.11
$0.26
(1.54%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00